Imagine a crowded clinic where patients with failing eyesight wait for a life-changing injection. The drug works, but the cost is so high that many people cannot get it on time. Now imagine a version of that same drug that does the same job but costs less. That is the promise of a biosimilar for a medicine called ranibizumab.
This new analysis looks at what would happen if Jordan’s public health system switched to this lower-cost version. The goal is to save money without cutting corners on care. For patients, that could mean more timely appointments and fewer delays.
Retinal diseases are conditions that damage the back of the eye, the part that helps you see clearly. One common problem is age-related macular degeneration, which can blur central vision. Another is diabetic macular edema, which causes swelling in the retina. These conditions affect many people in Jordan and around the world. The standard treatment is regular injections into the eye to keep vision stable. The medicine used is often ranibizumab, which is effective but expensive.
When a drug is expensive, health systems face tough choices. They may limit how many patients can get it, or they may ask patients to wait. This can lead to worse outcomes because delays in treatment can cause permanent vision loss. The frustration for patients and doctors is real. The need for a more affordable option is urgent.
But here is the twist. A biosimilar is not a cheap knockoff. It is a version of the original biologic medicine that is highly similar in safety and effectiveness. It is like a generic drug but for complex medicines made from living cells. The key difference is that biosimilars can be priced lower, which can ease the strain on health budgets.
Think of the original drug as a custom-built car. A biosimilar is a car made by another skilled team using the same blueprint. It drives the same way, meets the same safety standards, and gets you to your destination. The savings come from a more efficient manufacturing process and more competition in the market.
The study team in Jordan built a budget impact model. They looked at data from 2023 to 2026. They included how many people have retinal diseases, how many new cases appear each year, and how many doses of ranibizumab are used per patient. They also factored in another eye drug, aflibercept, and how the market might shift if a biosimilar version of ranibizumab becomes available.
The model assumed the biosimilar would enter the market in 2025 and that its price would drop further in 2026. The team tested different scenarios to see how savings change if more patients switch, if prices fall more or less, and if doctors use different treatment schedules. They also ran sensitivity analyses to check how robust the results are.
This does not mean the biosimilar is already available in Jordan.
The results were clear. Switching from aflibercept to ranibizumab’s biosimilar could save between 20.55 and 1,519.93 Jordanian dinars per patient each year. That is a percentage saving of about 3 to 35 percent, depending on the condition and treatment plan. For the public health system, the total budget impact over four years ranged from about 6.9 million to 21.2 million dinars. These numbers reflect different ways doctors might use the drug, such as treating on demand or extending the time between visits.
Patient access improved significantly in every scenario. The model showed that between 2.75 percent and 124.76 percent more patients could receive treatment. That means fewer people waiting and more people getting the injections they need to protect their vision. The exact gain depends on how many clinics adopt the biosimilar and how quickly prices fall.
But there is a catch. The savings are not automatic. They depend on how many patients switch to the biosimilar and how the market evolves. If uptake is slow, the financial impact will be smaller. If prices drop faster than expected, savings could be even greater.
Experts in health economics say that biosimilars are a key tool for making complex medicines more affordable. They note that the clinical outcomes remain the same, so the focus shifts to managing costs and expanding access. This analysis fits into a larger global trend where health systems are adopting biosimilars to stretch budgets without sacrificing care.
For patients in Jordan, this could mean more predictable access to a proven treatment. If you or a loved one has a retinal disease, it is worth asking your eye doctor about treatment options and whether a biosimilar might become available in the future. Do not stop any current treatment without medical advice.
The study has some limitations. It is a model, not a real-world trial. The results depend on assumptions about prices, uptake, and treatment patterns. Actual savings may vary once the biosimilar is launched and used in clinics.
Looking ahead, the next step is for health authorities and pharmaceutical companies to finalize pricing and distribution. If the biosimilar is approved and adopted, clinics in Jordan could start offering it in the coming years. Further research will track real-world savings and patient outcomes to confirm the model’s predictions.
